This site is intended for healthcare professionals. If you are a patient or caregiver, please contact your physician to discuss clinical trial eligibility.
Explore our pipeline of investigational medicines, featuring therapies designed to inhibit cancer-driving molecular targets in genetically defined pediatric and adult patient populations.
EARLY STAGE CLINICAL DEVELOPMENT
LATE STAGE CLINICAL DEVELOPMENT
* Marketing Authorization Application submitted by Bayer.
** Co-promotion between Loxo Oncology and Bayer.
For comprehensive details about these clinical trials, please refer to clinicaltrials.gov.
Policy for Access to Investigational Agents
Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology's Policy for Access to Investigational Agents describes the principles and government regulations that the company will follow when considering a request.